Medical Hypotheses
Volume 58, Issue 2 , Pages 127-132 , February 2002

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia

  • M.J. Fryer

      Affiliations

    • Correspondence to: Michael J. Fryer, PhD, Department of Biological Sciences, John Tabor Laboratories, University of Essex, Wivenhoe Park, Colchester, Essex CO4 3SQ, UK. Phone: +44 (0)1206 873333; Fax: +44 (0)1206 873416; E-mail: mfryer@essex.ac.uk

Received 2 March 2001 ,Accepted 5 July 2001.

References 

  1. Campuzano V, Montermini M, Molto MD. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;217:1423–1427
  2. Priller J, Scherzer CR, Faber PW, MacDonald ME, Young AB. Frataxin gene of Friedreich's ataxia is targeted to mitochondria. Ann Neurol. 1997;42:265–269
  3. Kayden H J. The neurologic syndrome of vitamin E deficiency: a significant cause of ataxia. Neurology. 1993;43:2167–2169
  4. Muller DPR. Vitamin E and neurological function: lessons from patients with abipoproteinaemia. Redox Report. 1995;1:239–245
  5. Ouachi K, Arita M, Kayden H. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nature Genet. 1995;9:141–145
  6. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Clarendon Press; 1999;
  7. Babcock M, De Silva D, Oaks R. Regulation of mitochondrial iron accumulation by YFH1p, a putative homolog of frataxin. Science. 1997;276:1709–1712
  8. Foury F, Cazzalini O. Detection of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. 1997;411:373–377
  9. Rotig A, De Lonlay P, Chretien D. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature Genet. 1997;17:215–217
  10. Leonard JV, Schapira AHV. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet. 2000;355:389–394
  11. Lodi R, Cooper JM, Bradley JL. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA. 1999;96:11492–11495
  12. Lodi R, Cooper JM, Bradley JL. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA. 1999;96:11492–11495
  13. Lodi R, Cooper JM, Bradley JL. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia. Proc Natl Acad Sci USA. 1999;96:11492–11495
  14. Rustin P, von Kleist-Retzow J-C, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet. 1999;354:477, 479
  15. Cohen A. Current status of iron chelation therapy with deferoxamine. Seminars Haematol. 1990;27:86–90
  16. Horackova M, Ponka P, Byczko Z. The antioxidant effects of a novel iron chelator salicylaldehyde isonicotinoyl hydrazone in the prevention of H2O2 injury in adult cardiomyocytes. Cardiovasc Res. 2000;47:529–536
  17. Vyth A, Trimmer JG, Bossuyt PMM, Louwerse ES, Vianney de Jong JMB. Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants. J Neurol Sci. 1996;139:99–103
  18. Schulz JB, Dehmer T, Schols L. Oxidative stress in patients with Friedreich ataxia. Neurology. 2000;55:1719, 1721
  19. Kassell NF, Haley EC, Apperson-Hansen C. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia and New Zealand. J Neurosurg. 1996;84:221–228
  20. Hall ED, Braughler JM, Yonkers PA. U-78517F: a potent inhibitor of lipid peroxidation with activity in experimental brain injury and ischaemia. J Pharmacol Exp Therapeutics. 1991;258:688–694
  21. Bracken MB, Shepard MJ, Holford TR. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. JAMA. 1997;277:1597–1604
  22. Rayman MP. The importance of selenium to human health. Lancet. 2000;356:233–241
  23. McCoy KEM, Weswig PH. Some selenium responses in the rat not related to vitamin E. J Nutr. 1969;98:383–389
  24. Fischer WC, Whanger PD. Effects of selenium deficiency on vitamin E metabolism in rats. J Nutr Sci Vitaminol. 1977;23:273–280
  25. Hakkarainen J, Lindberg P, Bengtsson G, Jonsson L, Lannek N. Requirement for selenium (as selenite) and vitamin E (as α-tocopherol) in weaned pigs. III: The effect on the development of the VESD syndrome of varying selenium levels in a low-tocopherol diet. J Animal Sci. 1978;46:1001–1008
  26. Van Fleet JF, Ferrans VJ, Ruth GR. Ultrastructural alterations in nutritional cardiomyopathy of selenium: vitamin E deficient swine. I: Fiber lesions. Lab Invest. 1977;37:188–200
  27. Grant CA. Morphological and aetiological studies of dietetic microangiopathy in pigs (‘mulberry heart’). Acta Vet Scand. 1961;2:1–107
  28. Cawley GD, Bradley R. Sudden death in calves associated with acute myocardial degeneration and selenium deficiency. Vet Rec. 1978;103:239–240
  29. Andrews ED, Hartley WJ, Grant AB. Selenium responsive diseases of animals in New Zealand. New Zealand Vet J. 1968;16:3
  30. Millar KR. Selenium in animal health and disease. In:  Kjellstron T,  Aggett J editor. Trace Elements in Human andAnimal Health and Disease in New Zealand. Hamilton: Waikato University Press; 1977;p. 84–88
  31. van Rij AM, Thomson CD, McKenzie JM, Robinson MF. Selenium deficiency in total parenteral nutrition. Am J Clin Nutr. 1979;32:2076–2085
  32. Thomson CD, Robinson MF. Selenium in human health and disease with emphasis on those aspects peculiar to New Zealand. Am J Clin Nutr. 1980;33:303–323
  33. Chen X, Yang G, Chen J, Chen X, Wen Z, Ge K. Studies on the relations of selenium and Keshan disease. Biol Trace Element Res. 1980;2:91–107
  34. Chen X, Yang G, Chen J, Chen X, Wen Z, Ge K. Studies on the relations of selenium and Keshan disease. Biol Trace Element Res. 1980;2:91–107
  35. Chen X, Yang G, Chen J, Chen X, Wen Z, Ge K. Studies on the relations of selenium and Keshan disease. Biol Trace Element Res. 1980;2:91–107
  36. Chen X, Yang G, Chen J, Chen X, Wen Z, Ge K. Studies on the relations of selenium and Keshan disease. Biol Trace Element Res. 1980;2:91–107
  37. Forbes GM, Forbes A. Micronutrient status in patients receiving home parenteral nutrition. Nutrition. 1997;13:941–944
  38. Johnson RA, Baker SS, Fallon JT. An Occidental case of cardiomyopathy and selenium deficiency. N Engl J Med. 1981;304:1210–1212
  39. Fleming CR, Lie JT, McCall JT, O'Brien JF, Baillie EE, Thistle JL. Selenium deficiency and fatal cardiomyopathy in a patient on home parenteral nutrition. Gastroenterology. 1982;83:689–693
  40. Sanchez-Casis G, Cote M, Barbeau A. Pathology of the heart in Friedreich's ataxia: review of the literature and report of one case. Can J Neurol Sci. 1976;3:349–354
  41. La Marche JB, Cote M, Lemieux B. The cardiomyopathy of Friedreich's ataxia: morphological observations in 3 cases. Can J Neurol Sci. 1980;7:389–396
  42. Helveston W, Hurd R, Uthman B, Wilder BJ. Abnormalities of glutathione peroxidase and glutathione reductase in four patients with Friedreich's disease. Mov Disord. 1996;11:106, 107
  43. Helveston W, Cibula JE, Hurd R, Uthman BM, Wilder BJ. Abnormalities of antioxidant metabolism in a case of Friedreich's disease. Clin Neuropharmacol. 1996;19:271–275

PII: S0306-9877(01)91474-4

doi: 10.1054/mehy.2001.1474

Medical Hypotheses
Volume 58, Issue 2 , Pages 127-132 , February 2002

Article Tools